Beyond Aortic Valve Replacement: Understanding Flow Dynamics and the Role of DurAVR THV

Rethinking Advanced Thyroid Cancer: Neoadjuvant Therapy and the Future of Surgery

In this episode of MedInsights Unleashed, John Collins speaks with Professor Gregory Randolph MD, FACS, FACE, Bertucci Chair in Thyroid Surgical Oncology at Harvard Medical School, about the evolving role of neoadjuvant therapy in advanced thyroid cancer. The discussion explores the challenges of locally invasive thyroid cancer and how neoadjuvant lenvatinib prior to surgery may help improve surgical outcomes, reduce morbidity, and preserve critical structures such as the recurrent laryngeal nerve. The conversation also highlights findings from a multicenter Phase 2 clinical trial, including promising results related to nerve preservation, vocal cord recovery, and the future of multidisciplinary thyroid cancer care.

CPR, CPR-102, AEDs, and DNRs: What Everyone Should Know in an Emergency

In this episode of MedInsights Unleashed, John Collins speaks with Devin Hinchcliffe about one of the most important life-saving interventions in medicine and emergency care — CPR. The discussion explores CPR fundamentals, CPR-102 updates, AED use, DNR considerations, and why rapid intervention by both healthcare professionals and members of the community can significantly improve outcomes during cardiac emergencies. Drawing from his experience in Emergency Medical Services, law enforcement, and EMS education, Devin provides practical insights into emergency response, first responder training, and the importance of public awareness and preparedness. This episode offers valuable information for healthcare professionals, caregivers, first responders, and members of the public who want a better understanding of CPR and emergency response.

Beyond Aortic Valve Replacement: Understanding Flow Dynamics and the Role of DurAVR THV

In this episode of MedInsights Unleashed, Wayne Paterson, Vice Chairman and CEO of Anteris Technologies, joins us to discuss one of the fastest evolving areas in structural heart disease — whether the future of valve replacement lies not only in replacing diseased valves, but also in restoring more natural heart flow. The discussion explores aortic stenosis, the evolution of TAVR, and the emerging science and MRI data surrounding DurAVR THV, including the potential importance of flow dynamics, laminar flow, durability, and long-term valve performance. We also discuss patient selection, future valve innovation, and how next-generation technologies may move beyond simply treating obstruction toward restoring more natural cardiovascular physiology.

The Prescription Journey: What Really Happens After Your Doctor Writes the Script

In this episode of MedInsights Unleashed, John Collins speaks with Patrick Coyle, MBA, about the often-overlooked journey patients face after receiving a prescription. The conversation explores the complex system behind drug access—including insurance coverage, copays, prior authorizations, and the role of pharmacies. Patrick provides insight into how financial and operational factors influence whether patients ultimately receive their prescribed treatment. The discussion also highlights key differences between branded and generic medications, the growing challenges in specialty therapies like oncology, and the importance of patient advocacy. This episode offers practical guidance for patients and caregivers on how to navigate the system, ask the right questions, and better understand the realities behind prescription access.

Rethinking Intermediate-Stage HCC: Evolution Beyond TACE as a One-Size-Fits-All Strategy

In this episode of MedInsights Unleashed, Professor Markus Peck-Radosavljević, MD, MBA—Professor of Medicine and Chairman of the Department of Internal Medicine & Gastroenterology at Klinikum Klagenfurt, Austria— discusses evolving treatment strategies in hepatocellular carcinoma (HCC). The conversation explores the changing role of transarterial chemoembolization (TACE) in intermediate-stage disease, emerging clinical evidence from studies such as REPLACEMENT Emerald-1 and LEAP-012, and how new systemic and immunotherapy approaches are reshaping treatment decisions. The discussion also highlights the importance of curative opportunities, multidisciplinary care, and maintaining overall survival as the most meaningful endpoint in liver cancer treatment.